Millendo therapeutics, inc. (OVAS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities:
Net loss

-11,998

-12,699

-11,632

-9,871

-10,366

-9,858

-7,891

-5,042

-4,386

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

37

45

33

11

8

9

8

9

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

1,080

1,187

1,196

995

939

668

423

159

177

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right-of-use asset

243

-

-

-

76

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign currency loss

-

-

-

-

-

-

-37

-64

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-9,366

-18,186

-14,895

-22,643

-19,291

-18,568

-21,758

-20,601

-17,922

-17,490

-17,206

-18,890

-12,923

-9,893

-7,814

-11,000

-6,891

-5,996

-5,157

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

360

490

461

593

578

563

504

538

348

200

200

188

114

82

66

62

69

53

47

Amortization of (discount) premium on debt securities

-

-

-

-

-

-

-

-

-

-

10

64

27

52

109

203

295

324

352

269

171

233

253

236

149

177

183

118

108

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

459

4,558

1,360

990

2,508

2,166

3,551

4,920

3,699

4,351

6,367

6,372

2,953

2,215

867

1,264

1,619

1,374

837

Issuance of common stock for director fees

-

-

-

-

-

-

-

-

-

-

28

36

38

38

39

39

38

165

0

0

0

-

-

-

-

-

-

-

-

Net loss on equity method investment

-

-

-

-

-

-

-

-

-

-

-140

-454

-421

-371

-364

-416

-391

-385

-316

-389

-471

-

-

-

-

-

-

-

-

Net loss on equity method investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

295

97

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-1,807

301

-2,513

2,748

162

1,677

86

595

166

-367

-664

487

-458

-403

1

-74

-470

-781

107

1,548

239

199

201

642

-45

-186

-76

435

-97

Other assets

1

231

-235

-121

59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

1,329

-1,281

-244

658

398

253

434

-165

-202

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

-

-

-

-584

917

184

-539

282

-1,299

378

-32

-527

1,045

-657

424

659

-167

1,401

-637

575

-732

73

Accrued expenses and other liabilities

-2,255

1,485

-312

399

-1,291

1,372

1,422

869

-423

4,046

-2,015

-186

-3,239

3,625

-24

487

721

2,201

1,329

750

-3,528

680

87

1,306

228

2,760

-181

454

-61

Operating lease liabilities

-403

-

-

-

-144

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash used in operating activities

-10,161

-11,691

-8,357

-10,573

-10,601

-9,226

-4,723

-4,701

-4,997

17,239

-10,304

-12,090

-15,185

-14,969

-15,436

-15,919

-15,410

-11,319

-12,522

-12,051

-14,394

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,961

-

-4,186

-5,164

-4,056

Investment in joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

0

750

-

0

750

750

0

0

0

1,500

-

-

-

-

Purchase of property and equipment

26

33

87

267

10

16

13

6

1

-108

11

26

75

1,541

177

498

370

2,906

1,175

759

389

-

-

-

-

212

273

50

184

Proceeds from sale of marketable securities

0

0

0

1,399

2,986

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash paid in Alizé asset purchase

-

-

-

-

-

0

0

0

524

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

-

-

-

-

-

17,607

26,907

23,325

27,005

9,595

14,599

20,814

12,424

7,375

14,699

19,030

3,977

2,500

9,606

4,714

-

-

-

-

Proceeds from sale of property, plant and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,013

2,003

0

4,415

-

-

-

-

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

4,927

16,914

26,562

17,038

38,491

24

27,118

13,153

13,154

68,918

0

0

-1

41,331

16,273

-

-

-

-

(Decrease) increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-109

-88

-

0

439

0

-

-

-

-

-

-

-

-

Cash (used in) provided by investing activities

-26

-33

-87

1,132

2,976

2,476

-13

-6

-525

-18,316

12,119

9,967

-3,312

8,426

-30,073

37,275

-7,336

3,823

-6,954

-53,050

17,891

-

-

-

-

-

-

-

-

Financing activities:
Repayment of debt

0

-

44

45

45

-

41

41

43

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of financing costs

197

-245

83

147

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,644

-

-2,764

-9,833

-184

Proceeds from the issuance of common stock, net of issuance costs

5,718

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

124,063

179

-85

-22

51,661

-74

-166

2

32,652

Proceeds from option and warrant exercises

78

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of principal on finance lease

10

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuances of common stock under benefit plans, net of withholding taxes paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80

641

724

-

-

-

-

-

-

-

-

Cash provided by (used in) financing activities

5,589

26,860

121

22

-60

70,610

7,700

-523

-43

-4,463

0

0

0

-7

95

54,060

0

-122

80

641

124,787

-

-

-

-

-

-

-

-

Effect of foreign currency exchange rate changes on cash

-37

-

40

-21

-14

-

-20

-34

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-4,635

15,164

-8,283

-9,440

-7,699

64,002

2,944

-5,264

-5,535

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51,661

-

-166

2

32,652

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

1,815

-2,123

-18,497

-6,550

-45,414

75,416

-22,746

-7,618

-19,396

-64,460

128,284

-5,711

-4,428

-39,581

38,056

-2,999

-7,116

-14,995

28,412

Alizé acquisition costs included in accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

26

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs in accounts payable and accrued expenses

68

-

-

23

60

-714

570

112

47

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-